Meriofert Kit

Follicle-Stimulating Hormone; Luteinising Hormone, the active ingredient in Meriofert Kit, is a gonadotropin presented as a sterile injectable solution for subcutaneous use. It is employed in reproductive medicine to stimulate follicular development, ovulation and luteinisation in women with anovulatory infertility or hypogonadotropic hypogonadism.

GNH USA supplies Meriofert Kit as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, fertility clinics and pharmacies worldwide. The company adheres to stringent quality standards and provides cold‑chain logistics where required.

Meriofert Kit, containing FSH and LH, acts on the hypothalamic‑pituitary‑gonadal axis to support reproductive function.

Infertility due to anovulation: promotes follicular growth and ovulation in women who do not ovulate spontaneously. Assisted reproductive technology (ART) protocols: provides controlled ovarian stimulation for IVF and ICSI cycles. Hypogonadotropic hypogonadism: replaces deficient gonadotropins to restore normal ovarian activity.

Adverse reactions may occur with any gonadotropin therapy.

Common Side Effects: - Injection site pain or erythema - Mild abdominal discomfort or bloating - Nausea or mild vomiting - Headache - Transient ovarian hyperstimulation (mild) - Fatigue

Serious or Rare Side Effects: - Severe ovarian hyperstimulation syndrome - Thromboembolic events - Allergic reaction or anaphylaxis - Multiple pregnancy - Ectopic pregnancy - Vision disturbances or retinal detachment

Use of Meriofert Kit requires careful clinical monitoring. - Assess ovarian response before initiating therapy: baseline ultrasound and hormone levels. - Monitor estradiol and follicle size during stimulation. - Avoid in patients with known hypersensitivity to gonadotropins. - Use caution in women with ovarian cysts, endometriosis or uncontrolled thyroid disease. - Do not exceed the recommended number of stimulation cycles per year. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Gonadotropin therapy can be affected by other hormonal agents.

Major Interactions (Avoid): - GnRH agonists: may blunt response if timing is incorrect. - Oral contraceptives: suppress endogenous gonadotropins, reducing efficacy. - High‑dose estrogen therapy: antagonises FSH/LH action.

Moderate Interactions (Monitor Closely): - Anticoagulants: increased risk of ovarian bleeding. - Thyroid hormone replacement: may alter ovarian response. - Corticosteroids: can affect hormone metabolism and response.